Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA is requiring all GLP-1 receptor agonist manufacturers to add a warning about nonarteritic anterior ischemic optic neuropathy (NAION) — a rare but serious eye condition — to their drug labels. A meta-analysis of 126 clinical trials found a higher rate of NAION in GLP-1 users compared to those on other therapies. Clinicians are advised to counsel patients on sudden vision changes and consider referral to an ophthalmologist if NAION is suspected.
The FDA has issued a drug safety communication requiring manufacturers of all GLP-1 receptor agonists — including semaglutide — to add a warning about the risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, painless vision loss. The move follows a 2024 JAMA Ophthalmology study that flagged a potential link between semaglutide and NAION, prompting the agency to investigate further.
To assess the risk, the FDA analyzed data from 126 clinical trials and a large real-world database spanning 2019–2024. While the absolute risk remains low, GLP-1 users showed a higher incidence of NAION compared to those on placebo or non-GLP-1 diabetes medications. Experts stress that causality isn't confirmed — diabetes, hypertension, and vascular disease are themselves NAION risk factors — and that the well-established cardiovascular and metabolic benefits of GLP-1s should still guide treatment decisions.
By the Numbers:
Why it matters: With GLP-1 therapies now central to diabetes and obesity care, this labeling update is a critical reminder for clinicians to screen for eye symptoms and engage in shared decision-making — especially for patients with prior NAION or significant vascular risk factors.
